10 Stocks With Low Debt and Strong Free Cash Flow
Low debt and strong free cash flow give a company room to keep investing when demand weakens, financing becomes less attractive or competitors need to conserve cash.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 1,126,080 | $702,155,889 | -9% | 0.24% |
| 2. | GLG Partners Noam Gottesman | 436,956 | $272,459,544 | +39% | 0.43% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 393,685 | $245,478,345 | +130% | 0.11% |
| 4. | 271,300 | $169,166,402 | +27% | 0.02% | |
| 5. | 264,600 | $164,988,684 | +54% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $857.39 | 1,131 | $969,708.09 | 12,003 | 2026-09-03 | Filing | |
| $850.00 | 1,215 | $1,032,750.00 | 13,134 | 2026-09-02 | Filing | |
| $850.00 | 400 | $340,000.00 | 603 | 2026-09-02 | Filing | |
| $800.00 | 400 | $320,000.00 | 603 | 2026-08-10 | Filing | |
| $800.00 | 800 | $640,000.00 | 1,703 | 2026-08-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 67,300 | $51,031,571 | 4.39% | |
| 2. | 16,110 | $12,215,730 | 2.05% | |
| 3. | 9,212 | $6,985,183 | 0.18% | |
| 4. | 2,687 | $2,037,471 | 0.21% | |
| 5. | 1,461 | $1,108,141 | 0.22% |
News See All
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage.
Here's Why The Fund Sold Regeneron Pharmaceuticals (REGN)
American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”.
Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock
Harbor Funds, an investment management company, released its Q2 2026 investor letter for “Harbor Mid Cap Value Fund”. The letter can be downloaded here.
Can Regeneron (REGN)'s Rare-Disease Win Move the Earnings Needle?
The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva.
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here.
Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims
A class action lawsuit was filed against biotechnology company Regeneron ($REGN) on July 16, which could put further pressure on its troubled share...
The Week That Was, The Week Ahead: Macro and Markets, August 16
U.S. stocks ended another positive week near record highs, although Friday’s weak retail sales report took some of the shine off the rally. The S&P...
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology.
Measuring the Beat: 57 Stocks Surpassing Earnings Expectations
Academic research has consistently found that corporate earnings surprises cluster around small positive values, rather than large outperformance.
Hedge Fund Resource Center